Keywords: GlaxoSmithKline, Avandia, Diabetes, Cardiovascular risks, FDA advisory panel vote, Legal charges

US FDA advisory panels vote to keep GlaxoSmithKline’s diabetes drug Avandia on the market; GSK updates on legal issues

Article | 15 July 2010

Print This

To the delight of GlaxoSmithKline, but no doubt to the surprise - even dismay - of others, US Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in